Login to Your Account

Optimer's C. Diff Drug Lures Regional Astellas Partnership

By Jennifer Boggs

Tuesday, February 8, 2011
Worries that generic vancomycin could cut into the market potential for Optimer Pharmaceuticals Inc.'s Clostridium difficile infection (CDI) drug fidaxomicin have been eased somewhat, with Astellas Pharma Europe Ltd. jumping on board in a potential $224 million regional deal.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription